This morning's Telegraph reports that NICE has turned down the kidney cancer drug called everolimus because it does not offer enough benefit to patients to justify the cost. An estimated eight week cycle of treatment would cost £5,264 per patient and could extend life by 3 months. The cost per QALY is almost double what NICE would normally allow.
Sir Andrew Dillon, Chief Executive at NICE said: “A diagnosis of renal cancer is devastating for patients and those who care for them and we are disappointed not to be able to recommend everolimus as a second line treatment option. "However, we to have ensure that the money available to the NHS is used to best effect, particularly when NHS funds, like the rest of the public sector, is under considerable financial pressure.”
Tidak ada komentar:
Posting Komentar